<?xml version="1.0" encoding="us-ascii"?><InstanceReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><Version>2.4.0.8</Version><ReportLongName>108 - Disclosure - Basis of presentation</ReportLongName><DisplayLabelColumn>true</DisplayLabelColumn><ShowElementNames>false</ShowElementNames><RoundingOption /><HasEmbeddedReports>false</HasEmbeddedReports><Columns><Column FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><CurrencyCode /><FootnoteIndexer /><hasSegments>false</hasSegments><hasScenarios>false</hasScenarios><MCU><KeyName /><CurrencySymbol /><contextRef><ContextID>eol_PE715633--1310-Q0007_STD_181_20130630_0</ContextID><EntitySchema>http://www.sec.gov/CIK</EntitySchema><EntityValue>0001369786</EntityValue><PeriodDisplayName /><PeriodType>duration</PeriodType><PeriodStartDate>2013-01-01T00:00:00</PeriodStartDate><PeriodEndDate>2013-06-30T00:00:00</PeriodEndDate><Segments /><Scenarios /></contextRef><UPS /><CurrencyCode /><OriginalCurrencyCode /></MCU><CurrencySymbol /><Labels><Label Key="CalendarSupplement" Id="0" Label="6 Months Ended" /><Label Key="Calendar" Id="1" Label="Jun. 30, 2013" /></Labels></Column></Columns><Rows><Row FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>4</Level><ElementName>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><PreferredLabelRole>terseLabel</PreferredLabelRole><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="eol_PE715633--1310-Q0007_STD_181_20130630_0" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText>&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note 1. Basis of
presentation:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Our interim condensed
consolidated financial statements are unaudited. We prepared the
condensed consolidated financial statements following rules for
interim reporting as prescribed by the U.S. Securities and Exchange
Commission (&amp;#x201C;SEC&amp;#x201D;). As permitted under those rules, we
have condensed or omitted a number of footnotes or other financial
information that are normally required by accounting principles
generally accepted in the United States of America (&amp;#x201C;U.S.
GAAP&amp;#x201D;). It is management&amp;#x2019;s opinion that these financial
statements include all adjustments, consisting of normal and
recurring adjustments, necessary for a fair presentation of our
financial position, operating results and cash flows. Operating
results for any interim period are not necessarily indicative of
future or annual results.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are organized as a
single reportable segment comprised of operations which develop,
source and market generic injectable products for sale in the
United States, deriving a significant portion of our revenues from
a single class of pharmaceutical wholesale customers in the United
States.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The condensed consolidated
financial statements include Sagent as well as our wholly owned
subsidiaries. All material intercompany balances and transactions
have been eliminated in consolidation. We account for our
investment in Sagent Agila LLC (formerly Sagent Strides LLC) using
the equity method of accounting, as our interest in the entity
provides for joint financial and operational control.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On June&amp;#xA0;4, 2013, we
acquired the remaining 50% equity interest in Kanghong Sagent
(Chengdu) Pharmaceutical Co. Ltd., (&amp;#x201C;KSCP&amp;#x201D;) from our
former joint venture partner, and accordingly, the condensed
consolidated balance sheet as of June&amp;#xA0;30, 2013 includes KSCP
as a wholly-owned subsidiary. Prior to the acquisition, we
accounted for our investment in KSCP using the equity method of
accounting, as our interest in the entity provided for joint
financial and operational control. Operating results of KSCP, prior
to the acquisition of the remaining 50% equity interest, are
reported on a one-month lag.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;You should read these
statements in conjunction with our consolidated financial
statements and related notes for the year ended December&amp;#xA0;31,
2012, included in our Annual Report on Form 10-K filed with the SEC
on March&amp;#xA0;18, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill is recognized as
the excess cost of an acquired entity over the net amount assigned
to assets acquired and liabilities assumed. Goodwill is not
amortized, but rather tested for impairment on an annual basis and
more often if circumstances require. Impairment losses are
recognized whenever the implied fair value of goodwill is less than
its carrying value. We test goodwill for impairment at least
annually on October&amp;#xA0;1.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;i&gt;Property, Plant, and
Equipment&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant, and
equipment is stated at cost, less accumulated depreciation. The
cost of repairs and maintenance is expensed when incurred, while
expenditures for refurbishments and improvements that significantly
add to the productive capacity or extend the useful life of an
asset are capitalized. Provisions for depreciation are computed for
financial reporting purposes using the straight-line method over
the estimated useful life of the related asset and for leasehold
improvements over the lesser of the estimated useful life of the
related asset or the term of the related lease as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="51%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td width="47%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Land and land improvements&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Remaining term of Chinese land use right&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Building and improvements&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5 to 40 years or remaining term of leasehold&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Machinery, equipment, furniture, and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3 to 10 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property, plant and
equipment that is purchased or constructed which requires a period
of time before the assets are ready for their intended use are
accounted for as construction-in-progress. Construction-in-progress
is recorded at acquisition cost, including installation costs and
associated interest costs. Construction-in-progress is transferred
to specific property, plant and equipment accounts and commences
depreciation when these assets are ready for their intended use.
The capitalization of interest costs commences when expenditures
for the asset have been made, activities that are necessary to
prepare the asset for its intended use are in progress and interest
cost is being incurred. The capitalization period ends when the
asset is substantially complete and ready for its intended
use.&lt;/font&gt;&lt;/p&gt;


&lt;/div&gt;</NonNumbericText><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>nonnum:textBlockItemType</ElementDataType><SimpleDataType>na</SimpleDataType><ElementDefenition>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</ElementDefenition><ElementReferences>No definition available.</ElementReferences><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Basis of presentation</Label></Row></Rows><Footnotes /><IsEquityReport>false</IsEquityReport><ReportName>Basis of presentation</ReportName><MonetaryRoundingLevel>UnKnown</MonetaryRoundingLevel><SharesRoundingLevel>UnKnown</SharesRoundingLevel><PerShareRoundingLevel>UnKnown</PerShareRoundingLevel><ExchangeRateRoundingLevel>UnKnown</ExchangeRateRoundingLevel><HasCustomUnits>true</HasCustomUnits><IsEmbedReport>false</IsEmbedReport><IsMultiCurrency>false</IsMultiCurrency><ReportType>Sheet</ReportType><RoleURI>http://www.sagentpharma.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</RoleURI><NumberOfCols>1</NumberOfCols><NumberOfRows>1</NumberOfRows></InstanceReport>
